{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the (U.S.) Patents and Patent Applications listed in the Supplementary Information section of this notice to GLG Pharma LLC located in Jupiter, Florida, USA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2019/05/23/2019-10779.html","cfr_references":[],"citation":"84 FR 23798","comment_url":null,"comments_close_on":"2019-06-07","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before June 7, 2019 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2019-10779","effective_on":null,"end_page":23799,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2019/05/23/2019-10779.xml","html_url":"https://www.federalregister.gov/documents/2019/05/23/2019-10779/prospective-grant-of-an-exclusive-patent-license-the-development-and-use-of-a-therapeutic-stat3","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2019-10779?publication_date=2019-05-23","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2019-05-23/2019-10779/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":334,"last_updated":"2026-09-22 16:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-05-23/pdf/2019-10779.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2019-10779.pdf?1558529118","publication_date":"2019-05-23","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2019/05/23/2019-10779.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T19:17:14Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":23798,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: The Development and Use of a Therapeutic STAT3 Inhibitor, GLG-302, in All Proliferative Diseases, Where STAT3 Is Present","toc_doc":"Development and Use of a Therapeutic STAT3 Inhibitor, GLG302, in All Proliferative Diseases, Where STAT3 is Present","toc_subject":"Prospective Grant of an Exclusive Patent License:","topics":[],"type":"Notice","volume":84}